Precipio logo
Precipio PRPO
$ 28.85 0.02%
report update icon

Quarterly report 2026-Q1
added 05-14-2026

Precipio Income Statement 2025-2008 | PRPO

Brief overview of income trends at Precipio

The comparison covers a five-year financial horizon. Revenue reported by Precipio was 6.1 million dollars at the beginning of the period and 24 million dollars at the end. The cumulative result was +294.8%, corresponding to roughly 31.6% per year. Revenue growth reflects a pronounced phase of business expansion.

Gross profit was 1.1 million dollars at the start and 10.7 million dollars at the end of the period (+831%). Revenue outpaced cost of revenue, allowing more sales to flow into gross profit. The gross margin was 18.9% at the start and 44.5% at the end. Improving gross profitability strengthens the quality of revenue growth.

The operating result measured by EBITDA moved from −$7.8 million to $43 thousand, or +100.6%. The operating result developed less favorably than sales. At the operating-margin level, the figure shifted from −127.9% to 0.2%. A wider margin confirms stronger operating efficiency.

Comparing the endpoints shows a move from −$10.6 million to −$363 thousand. The loss narrowed, although sustainable profitability has not yet returned.

Conclusion

The financial profile remains mixed, with strengths and risks moving in different directions. The financial profile benefits from higher operating efficiency, improving net profitability and a stronger gross margin. The most visible risks are a low EBITDA margin. Further direction will depend on top-line growth, operating profitability, and net income.

Annual Income Statement Precipio

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Market Cap

38.4 M 35 M 8.7 M 774 K 32.3 M 45.5 M 11 M 4.22 M 5.34 M 16.1 M 7.89 M 28 M - - - - - -

Shares

1.61 M 1.47 M 1.3 M 1.14 M 21.1 M 16 M 5.7 M 1.44 M 309 K 50.4 K 27.4 K 16.7 K - - - 49.2 M - -

Historical Prices

23.9 23.9 6.7 0.68 1.53 2.44 1.53 2.37 9.6 - - - - - - - - -

Net Income

-363 K -4.29 M -5.85 M -12.2 M -8.52 M -10.6 M -13.2 M -15.7 M -20.7 M -7.62 M -33 M -13.9 M -16 M -8.33 M -9.78 M -3.13 M -1.92 M -

Revenue

24 M 18.5 M 15.2 M 9.41 M 8.85 M 6.09 M 3.13 M 2.86 M 1.72 M 1.56 M 1.65 M 27.1 M 27.5 M 31.5 M 32 M - - -

Cost of Revenue

13.3 M 11 M 9.18 M 6.9 M 6.46 M 4.94 M 2.91 M 2.64 M 1.43 M 970 K 1.94 M 2.18 M 16.8 M 18.3 M 13.5 M 10.3 M 10.4 M -

Gross Profit

10.7 M 7.56 M 6.02 M 2.51 M 2.39 M 1.15 M 219 K 225 K 292 K -205 K -287 K 9.72 M 12.5 M 15 M 18.4 M 9.76 M 11.6 M -

Operating Income

-1.2 M -4.22 M -7.62 M -12.8 M -9.61 M -9.15 M -11 M -13.9 M -15.5 M -1.71 M -8.92 M -10.6 M -15.8 M -9.5 M -2.97 M -3.61 M -1.9 M -

Interest Expense

839 K -74 K - - - - - - - -1 K -14 K - 60 K 11 K 259 K 632 K 3 K -

EBITDA

43 K -3.02 M -6.4 M -11.6 M -8.48 M -7.79 M -7.99 M -7.96 M -5.45 M -7.56 M -8.71 M -15.1 M -13 M -7.23 M -830 K -2.9 M -1.04 M -

Operating Expenses

11.9 M 11.8 M 13.6 M 15.3 M 12 M 10.3 M 9.62 M 9.45 M 6.49 M 7.61 M 8.91 M 27 M 28.3 M 24.5 M 21.4 M 13.4 M 13.5 M -

General and Administrative Expenses

- - - - - - - 9.45 M 6.49 M - - - - - - 10.9 M 10.3 M -

All numbers in USD currency

Quarterly Income Statement Precipio

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

1.78 M 1.64 M 1.51 M 1.5 M 1.49 M 1.48 M 1.46 M 1.42 M 1.42 M 1.39 M 1.22 M 1.16 M 1.14 M 1.14 M 22.7 M 22.7 M 22.7 M 22.7 M 21 M 17.9 M 17.6 M 16 M 11.4 M 8.37 M 7.9 M 6.19 M 5.66 M 3.44 M 2.3 M 1.55 M 1.38 M 838 K 10.2 M 7.43 M 581 K 450 K 449 K 435 K 430 K 20.3 M 13.9 M 13.8 M 12.1 M 9.39 M 8.08 M 7.35 M 7.35 M 7.35 M 7.35 M 7.35 M 7.35 M 7 M 5.97 M 71.6 M 71.6 M 62.7 M 49.6 M 49.6 M 49.6 M 49.6 M

Net Income

-1.44 M -79 K 74 K -884 K - -626 K -1.22 M -2.08 M - -1.46 M -2.29 M -3.03 M - -3.17 M -2.14 M -4.58 M - -1.85 M -3.01 M -1.45 M - -3.29 M -2.23 M -3.2 M - -1.9 M -5.91 M -1.65 M - -3.85 M -2.83 M -2.44 M - -6.28 M -3.68 M -758 K - -499 K -444 K -3.26 M - -7.3 M -3.28 M -3.04 M -5.79 M -80 K -13.9 M -13.9 M -3.98 M -16 M -16 M -16 M -2.31 M -8.33 M -563 K -2.7 M 264 K -1.27 M -6 M -2.78 M

Revenue

6.71 M 6.77 M 5.65 M 4.93 M - 5.21 M 4.44 M 3.43 M - 4.52 M 3.53 M 2.82 M - 2.22 M 2.36 M 2.45 M - 2.25 M 2.34 M 1.82 M - 1.63 M 1.31 M 1.22 M - 784 K 942 K 713 K - 650 K 817 K 712 K - 270 K 260 K 658 K - 457 K 505 K 236 K - 330 K 442 K 750 K 7.7 M 4.06 M 6.76 M 6.25 M 6.22 M 6.65 M 7.31 M 7.37 M 7.29 M 7.89 M 9.09 M 7.21 M 8.57 M 8.25 M 7.67 M 7.48 M

Cost of Revenue

3.99 M 3.76 M 3.22 M 2.79 M - 2.93 M 2.72 M 2.51 M - 2.63 M 2.16 M 2.07 M - 1.78 M 1.59 M 1.74 M - 1.72 M 1.59 M 1.36 M - 1.25 M 1.14 M 1.09 M - 756 K 770 K 675 K - 661 K 642 K 688 K - 347 K 284 K 182 K - 231 K 241 K 505 K - 445 K 465 K 465 K - 2.35 M 4.37 M 3.76 M - 4.2 M 4.33 M 4.12 M - 4.09 M 4.53 M 4.1 M - 3.81 M 3.11 M 3.33 M

Gross Profit

2.72 M 3 M 2.43 M 2.14 M - 2.28 M 1.72 M 920 K - 1.88 M 1.37 M 749 K - 436 K 773 K 703 K - 528 K 751 K 468 K - 377 K 171 K 125 K - 28 K 172 K 38 K - -11 K 175 K 24 K - -77 K -24 K 66 K - 134 K 263 K -269 K - -115 K -23 K 285 K 2.62 M 1.72 M 2.39 M 2.49 M 2.08 M 2.45 M 2.97 M 3.26 M 3.54 M 3.8 M 4.56 M 3.1 M 5.28 M 4.44 M 4.56 M 4.15 M

Operating Income

-1.43 M -61 K -824 K -859 K - -597 K -1.21 M -2.07 M - -1.45 M -2.29 M -3.03 M - -3.23 M -2.43 M -4.81 M - -2.44 M -2.13 M -2.14 M - -2.43 M -2.26 M -2.2 M - -2.36 M -2.3 M -2.06 M - -4.12 M -2.18 M -2.45 M - -3.63 M -801 K -596 K - -363 K -285 K -2.24 M - -2.26 M -2.4 M -1.97 M - -3.99 M -3.96 M -3.54 M - -5.41 M -2.92 M -3.82 M - -2.43 M -1.37 M -2.44 M - -439 K -1.62 M -750 K

Interest Expense

- -18 K 898 K - - -29 K -11 K - - - - - - - - - - - - - - - - - - - - - - 268 K -648 K - - -2.65 M -2.88 M - - - - - - -6 K - -13 K - -1 K - - - 1 K - 53 K - -6 K 8 K 20 K - -2 K 1 K 231 K

EBITDA

-1.15 M - - -535 K - - - -1.77 M - - - -2.72 M - -2.32 M -1.83 M -4.51 M - -1.6 M -1.58 M -1.87 M - -1.6 M -1.7 M -1.92 M - -1.52 M -1.74 M -1.78 M - -3.14 M -1.5 M -2.1 M - -3.24 M -753 K -572 K - -264 K -230 K -2.16 M - -1.91 M -1.84 M -1.93 M - -3.4 M -3.47 M -3.05 M - -4.74 M -2.24 M -3.08 M - -1.93 M -838 K -1.93 M - 42 K -1.12 M -256 K

Operating Expenses

4.15 M 3.07 M 3.25 M 3 M - 2.87 M 2.92 M 2.99 M - 3.33 M 3.66 M 3.78 M - 3.66 M 3.21 M 5.51 M - 2.97 M 2.88 M 2.6 M - 2.81 M 2.43 M 2.33 M - 2.39 M 2.47 M 2.1 M - 4.11 M 2.36 M 2.47 M - 3.56 M 777 K 662 K - 497 K 548 K 1.97 M - 2.14 M 2.38 M 2.26 M - 5.7 M 6.35 M 6.03 M - 7.86 M 5.9 M 7.08 M - 6.23 M 5.93 M 5.54 M - 4.88 M 6.18 M 4.9 M

General and Administrative Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - 2.39 M 2.47 M 2.1 M - 2.83 M 2.36 M 2.18 M - 2.54 M 777 K 662 K - 497 K 1.44 M 1.7 M - 1.69 M 1.91 M 1.8 M - 5.06 M 5.56 M 5.29 M - 7.23 M 4.98 M 6.31 M - 5.56 M 5.28 M 4.99 M - 4.36 M 5.59 M 4.32 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Precipio (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Biomerica Biomerica
BMRA
$ 2.14 1.9 % $ 4.92 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.17 0.88 % $ 6.37 M usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Co-Diagnostics Co-Diagnostics
CODX
$ 1.21 0.79 % $ 1.61 M usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Brainsway Ltd. Brainsway Ltd.
BWAY
$ 14.3 0.7 % $ 486 M israelIsrael
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 242.76 0.02 % $ 26.9 B usaUSA
Celcuity Celcuity
CELC
$ 88.44 3.05 % $ 4.14 B usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Charles River Laboratories International Charles River Laboratories International
CRL
$ 291.5 0.16 % $ 14.4 B usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 6.77 1.18 % $ 27 M israelIsrael
DexCom DexCom
DXCM
$ 90.82 1.71 % $ 35.4 B usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
- - $ 2.69 B usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 398.58 0.64 % $ 28.8 B schweizSchweiz
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
Myriad Genetics Myriad Genetics
MYGN
$ 3.16 1.92 % $ 293 M usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
ENDRA Life Sciences ENDRA Life Sciences
NDRA
$ 5.01 4.53 % $ 3.94 M usaUSA
NeoGenomics NeoGenomics
NEO
$ 18.05 7.31 % $ 2.31 B usaUSA
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
National Research Corporation National Research Corporation
NRC
$ 21.85 0.27 % $ 489 M usaUSA
T2 Biosystems T2 Biosystems
TTOO
- -39.35 % $ 313 K usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 3.48 1.11 % $ 113 K usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
Meridian Bioscience Meridian Bioscience
VIVO
- - $ 1.49 B usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 1.4 0.32 % $ 420 M usaUSA
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 170.02 0.18 % $ 13.3 B irlandaIrlanda
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
Interpace Biosciences Interpace Biosciences
IDXG
$ 1.45 2.11 % $ 6.41 M usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 261.75 0.05 % $ 45 B usaUSA
Surmodics Surmodics
SRDX
- - $ 608 M usaUSA